Science & Innovation
For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 168,000 people worldwide.
Our world-class neurology research and development organization is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
We are fearless in advancing the treatment of depression to transform the lives of those living with or impacted by this diagnosis. It is estimated that fewer than one-third of people living with depression receive adequate treatment and one in two women with postpartum depression are never diagnosed.
As part of our long-standing efforts in neuroimmunology, we are utilizing our deep expertise in multiple sclerosis, our knowledge of immunological pathways, and our scientific and development synergies to positively impact the lives of people living with serious autoimmune diseases such as lupus.
Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help produce new therapeutic solutions that may bring us closer to a cure for MS.
Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for individuals afflicted with the debilitating disease.